Lyell Immunopharma, Inc. — Director's Dealing 2021

Dec 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2021-12-14

Reporting Person: FRIEDMAN CATHY (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-14	Common Stock	J	3765842	$0.00	Disposed	0	Indirect
2021-12-14	Common Stock	J	218722	$0.00	Acquired	236370	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	100000	Indirect

Footnotes

F1: Pro-rata distribution by Lyell Investors, LLC to its members.

F2: Received in a pro-rata distribution from Lyell Investors, LLC. The Reporting Person is a trustee of MSL FBO J DUANE & C FRIEDMAN TTEE DUANE FAMILY TRUST ("Duane Family Trust") and therefore may be deemed to share the power to direct the disposition and vote of the shares held by the Duane Family Trust. The Reporting Person disclaims beneficial ownership of all shares held by Duane Family Trust except to any pecuniary interest therein.

F3: The Reporting Person is a trustee of The Duane Irrevocable Trust 2020 ("Duane Irrevocable Trust") and therefore may be deemed to share the power to
direct the disposition and vote of the shares held by the Duane Irrevocable Trust. The Reporting Person disclaims beneficial ownership of all shares held by Duane Irrevocable Trust except to any pecuniary interest therein.